Introduction
============

Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used in the management of type 2 diabetes worldwide [@b1]. Their superior glucose-lowering effect in Asian people with type 2 diabetes, which is characterized by non-obesity and impaired insulin secretion, has promoted the use of these drugs in Asia [@b2]--[@b4]. The potential risk of pancreatitis and pancreatic cancer has been of concern from the early stages of DPP-4 inhibitor development. To ascertain whether or not DPP-4 inhibitors are associated with pancreatitis or pancreatic cancer, several investigations have been undertaken [@b5]--[@b7], including studies using claims databases, spontaneous reporting of clinical events, and brain-dead donors, in addition to systematic reviews based on various randomized clinical trials addressing the efficacy and the safety of DPP-4 inhibitors; however, published data on pancreatitis and/or pancreatic cancer associated with DPP-4 inhibitors focused on type 2 diabetes in Asian populations is limited.

In this study, we analyse a Japanese medical and pharmacy claims database to evaluate any association of acute pancreatitis (AP) with the use of DPP-4 inhibitors in Japanese patients with diabetes.

Materials and Methods
=====================

We used the Japan Medical Data Centre Claims Database (Japan Medical Data Centre Co., Ltd, Tokyo, Japan), which contains the following information on individuals aged \<75 years in employment-based health insurance programmes: age and gender of patient; diagnosis of disease using International Classification of Diseases (ICD)-10 code; and prescribed drugs. The data can be tracked for each individual in chronological order, even if they used multiple medical institutions.

Patients aged 30--74 years with pharmacy and medical claims data for a continuous period of at least 12 months from 1 June 2009 to 31 August 2013 were included. This allowed a 6-month period for baseline observations and at least 6 months of observation after initiation of the index medication. Patients with diabetes were identified by the presence of at least one ICD-10 code of E10--E14 during the study. Patients with E11 (n = 27 962) and E14 (n = 93 280) were subjected to further analyses, while those with E10 (n = 2090), E12 (n = 4) and E13 (n = 614) were excluded. The index date was defined as the prescription date of the first claim for a new oral antidiabetes drug during the target period, 1 December 2009 to 28 February 2013. An antidiabetic drug was considered new if there were no claims for the medication during the preceding ≥6-month period. Patients with AP ≥6 months before or on the index date were excluded. Patients with other pancreatic diseases, for example, chronic pancreatitis, were not excluded. Patients treated with glucagon-like peptide-1 (GLP-1) receptor agonists before or on the index date were also excluded. The use of insulin was not taken into consideration. The observation period started on the index date and ended at the occurrence of one of the following events, whichever was earliest: (i) AP, (ii) initiation of another new antidiabetic drug or GLP-1 receptor agonist, (iii) end of observation period and (iv) end of eligibility. The same patients were included multiple times into different index drug groups if they met the criteria, which allowed the consideration of exposure to DPP-4 inhibitors before initiation of the drug whose risk for AP was being studied. AP was determined by a claim for ICD-10 code K85. The AP risk factors, comorbidities and comedications at baseline are summarized in Tables S1--S3, Supporting information.

The primary outcome was the first occurrence of AP after the index date. The DPP-4 inhibitor group was compared with the group of patients on other antidiabetic drugs using Fisher\'s exact test. Kaplan--Meier curves were constructed for each group to show the time to AP. The log-rank test was performed to analyse any significant difference between two groups in time to AP. Cox proportional hazard models were built to compare the adjusted risk of AP with drug therapy, age, sex and/or risk comorbidities as independent variables. The integrity of the database was tested by examining the adjusted risk of hypoglycaemia of antidiabetic drugs and insulin, which was consistent with our general knowledge (Tables S12--S14).

All analyses were performed using [sas]{.smallcaps} software 9.3 TS1M1 (SAS Institute Inc., Cary, NC, USA). A p value of \<0.05 was taken to indicate statistical significance.

Results
=======

The incidence of all AP and hospitalizations for AP in patients on DPP-4 inhibitors and other antidiabetic drugs is summarized in Table[1](#tbl1){ref-type="table"}. The frequency of the occurrence of AP, both all AP and hospitalizations for AP, was found to be similar in patients on DPP-4 inhibitors and those on other drugs (all AP, p = 0.6241; hospitalizations for AP, p = 0.1790). The presence or absence of previous exposure to DPP-4 inhibitors did not affect the occurrence of AP in patients on other drugs (all AP, p = 1.0000; hospitalizations for AP, p = 1.0000). The Kaplan--Meier curves for time to all AP and hospitalization for AP was similar in patients on DPP-4 inhibitors and those on other drugs ([Figure 1](#fig01){ref-type="fig"}). Time to AP in patients on other drugs, with or without previous exposure to DPP-4 inhibitors, did not differ ([Figure 1](#fig01){ref-type="fig"}). The adjusted AP risk, calculated by the Cox proportional hazard models, did not differ by current or previous exposure to DPP-4 inhibitors (Tables S4 and S5).

###### 

Incidence of all acute pancreatitis (AP) and hospitalizations for AP in patients on different oral antidiabetic drugs

                                                   Age, years   All acute pancreatitis   Hospitalized AP                                                                          
  -------------------------- ----- -------- ------ ------------ ------------------------ ----------------- --- ---- -------- ----------- ----- ---- --- ---- -------- ----------- -----
  All                              16 901   71.1   52.4         52.2--52.5               13                7   22   21 064   67 (0.40)   318   13   7   22   21 116   20 (0.12)   95
  DPP-4 inhibitors                 11 075   71.6   53.3         53.1--53.4               12                7   21   13 164   42 (0.38)   319   13   7   21   13 195   10 (0.09)   76
  Others                           5826     70.1   50.6         50.4--50.9               14                8   23   7900     29 (0.50)   367   14   8   23   7921     11 (0.19)   139
                             Yes   1483     68.8   50.7         50.2--51.2               13                9   20   1877     7 (0.47)    373   13   9   20   1882     2 (0.13)    106
                             No    4343     70.6   50.6         50.3--50.9               14                8   24   6024     22 (0.51)   365   14   8   24   6039     9 (0.21)    149
  Sulphonylureas                   3348     72.6   51.8         51.5--52.1               11                6   19   3786     12 (0.36)   317   11   6   19   3798     2 (0.06)    53
                             Yes   1308     71.3   51.6         51.2--52.1               11                7   18   1395     5 (0.38)    358   11   7   18   1400     1 (0.08)    71
                             No    2040     73.4   51.9         51.4--52.3               11                6   21   2391     7 (0.34)    293   11   6   21   2398     1 (0.05)    42
  Glinides                         902      71.6   52.0         51.4--52.6               9                 4   17   908      3 (0.33)    330   9    4   17   909      1 (0.11)    110
                             Yes   301      74.1   51.8         50.7--52.8               8                 4   13   251      1 (0.33)    399   8    4   13   251      0 (0.00)    0
                             No    601      70.4   52.1         51.3--52.9               10                5   19   657      2 (0.33)    304   10   5   19   658      1 (0.17)    152
  Biguanides                       4747     70.1   51.0         50.7--51.2               11                6   19   5231     11 (0.23)   210   11   6   19   5237     5 (0.11)    95
                             Yes   1659     71.7   51.8         51.3--52.2               11                7   17   1706     4 (0.24)    234   11   7   17   1707     2 (0.12)    117
                             No    3088     69.2   50.5         50.2--50.9               11                6   20   3525     7 (0.23)    199   11   6   20   3530     3 (0.10)    85
  Thiazolidines                    2125     71.4   51.9         51.5--52.3               11                6   18   2359     7 (0.33)    297   11   6   18   2365     1 (0.05)    42
                             Yes   710      67.3   51.9         51.3--52.6               10                6   15   666      2 (0.28)    300   10   6   15   668      0 (0.00)    0
                             No    1415     73.4   51.9         51.4--52.4               11                6   21   1694     5 (0.35)    295   11   6   21   1697     1 (0.07)    59
  α-glycosidase inhibitors         2691     72.1   52.1         51.7--52.5               11                6   19   2956     18 (0.67)   609   11   6   19   2968     7 (0.26)    236
                             Yes   808      70.4   52.2         51.6--52.9               10                6   16   762      4 (0.50)    525   10   6   16   763      1 (0.12)    131
                             No    1883     72.8   52.0         51.6--52.5               11                5   21   2194     14 (0.74)   638   11   5   21   2205     6 (0.32)    272

No statistically significant differences were observed in incidences of all AP and hospitalizations for AP between DPP-4 inhibitors and others (Fisher\'s exact tests). Previous exposure to DPP-4 inhibitors did not significantly affect incidences of all AP and hospitalizations for AP in patients on other oral antidiabetic drugs, sulphonylureas, glinides, biguanides, thiazolidines and α- glycosidase inhibitors (Fisher\'s exact tests). Other antidiabetic drugs include sulphonylureas, glinides, biguanides, thiazolidindiones and α-glycosidase inhibitors. CI, confidential interval; DPP-4, dipeptidyl peptidase-4; AP, acute pancreatitis.

![Kaplan--Meier curves for time to acute pancreatitis. Time to acute pancreatitis \[(A, C) all acute pancreatitis (AP); (B, D) hospitalizations for AP\] was analysed for patients on dipeptidyl peptidase-4 (DPP-4) inhibitors and those on other oral antidiabetic drugs (others), and all together \[(A, B) All\], and for patients on other antidiabetic drugs with or without previous exposure to DPP-4 inhibitors, and all together (C, D). Vertical lines indicate patients excluded for reasons other than AP (e.g. initiation of another new antidiabetic drug or GLP-1 receptor agonist, end of observation period or end of eligibility). The log-rank test did not show significant difference either between patients on DPP-4 inhibitors and those on other drugs (all AP, p = 0.4440; hospitalizations for AP, p = 0.1524) or between patients on other drugs with or without previous exposure to DPP-4 inhibitors (all AP, p = 0.9626; hospitalizations for AP, p = 0.6908). Other oral antidiabetic drugs included sulphonylureas, glinides, biguanides, thiazolidiones and α-glycosidase inhibitors.](dom0017-0430-f1){#fig01}

Discussion
==========

This study failed to show any association of AP, in both all patients with AP and those hospitalized for AP, with use of DPP-4 inhibitors in Japanese patients with diabetes. Our negative findings are consistent with the claims database-based retrospective observations carried out in the United States [@b8],[@b9]. Although the incidence of all AP in this study (318 cases per 100 000 patient-years) is much higher than that of previous epidemiological data (5--80 cases per 100 000 patient-years) [@b10], it is consistent with that reported in claims analyses previously, which show a two- to three-fold higher incidence of AP in patients with diabetes (400--600 cases per 100 000 patient-years) [@b9],[@b11].

This study has some important limitations and the results should be considered with these in mind. Most importantly, the non-random nature of the study might have introduced many confounders, such as obesity and tobacco use, as well as use of medications associated with AP. If physicians were aware of a possible risk of pancreatitis associated with DPP-4 inhibitors, they may have preferentially prescribed other antidiabetic drugs to patients perceived to be at higher risk. The higher AP risk posed by α-glycosidase inhibitors (Fisher\'s exact tests: all AP, p = 0.0095; hospitalization for AP, p = 0.0147; Cox proportional hazard models, Table S11) found in this study might be explained by such a prescription bias. In addition, our claims database data do not include potentially relevant demographic or clinical details, such as type and duration of diabetes, obesity, glycaemic and lipid control and alcohol consumption, or AP that may have occurred before the traceable periods within the database. Our analysis did not include adjustment for medication dose or adherence, and did not confirm that patients were taking the prescribed antidiabetic drugs. The limited number of patients on GLP-1 receptor agonists restricted meaningful analysis to only DPP-4 inhibitors (Tables S6--S10).

Despite these limitations, this study provides valuable information for physicians and patients with diabetes, especially those in Japan and other Asian countries. Our claims data analysis has the strength of allowing the observation of a large number of patients treated with antidiabetic drugs throughout the country. Furthermore, our claims data analysis has little chance of missing cases of AP because no secondary insurance policies are allowed in Japan and medical costs are not generally paid out-of-pocket by patients on insurance policies.

In conclusion, the present analysis did not find any increased risk of AP with use of DPP-4 inhibitors among patients with diabetes in Japan.
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Cox proportional hazards analysis for time to acute pancreatitis, comparing the presence or absence of previous exposure to dipeptidyl peptidase-4 inhibitors in patients on other oral antidiabetic drugs.
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Cox proportional hazards analysis for time to acute pancreatitis, comparing glucagon-like peptide 1 receptor agonists with other oral antidiabetic drugs.
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Cox proportional hazards analysis for time to acute pancreatitis, comparing α-glycosidase inhibitors with other oral antidiabetic drugs.
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Incidence of all hypoglycaemia and hospitalizations for hypoglycaemia in patients on various antidiabetic drugs.
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Incidence of all hypoglycaemia and hospitalizations for hypoglycaemia in patients on antidiabetic drugs with or without insulin, sulphonylurea or glinide combinations.
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Logistic regression analysis for hypoglycaemia risk, comparing various antidiabetic drugs.
